Search Results 51-60 of 422 for ⚠메이저사이트 [원탑보증.com/가입코드 111] 토토사이트 ⚠

1. High Blood Pressure Clinical Trials - Mayo Clinic Research

   Hypertension is a major risk factor for cardiovascular and renal disease, and a leading cause of premature mortality worldwide. Early hypertension studies ...

2. Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or In Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer - Mayo Clinic

   Erlotinib hydrochloride and cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known ...

3. A Study to Determine the Safety, Tolerability and Effect on Liver Histologic Parameters of ARO-AAT - Mayo Clinic

   The purpose of this study is to evaluate the safety, tolerability and effect on liver histologic parameters with administration of the investigational product, ...

4. ... 111,#N/A,117.00 301000082,HC ARSENIC ASSAY NOT URINE/SERUM/WB,167,#N/A,#N/A 301000083,HC ARSENIC ASSAY URINE/SERUM/WB EA,167,#N/A,177.00 301000084,HC ...

5. A Study of the Safety and Effectiveness of HBI-8000 with Nivolumab to Treat Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer - Mayo Clinic

   Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

6. Elevate CLL R/R: Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia - Mayo Clinic

   Elevate CLL R/R: Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia.

7. A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease - Mayo Clinic

   The primary objective is to evaluate whether macitentan 10 mg reduces N-terminal pro-brain natriuretic peptide (NT-pro-BNP) as compared to placebo in these ...

8. ALTA TIPS: A 5-year Longitudinal Observational Study of Patients Undergoing TIPS Placement - Mayo Clinic

   ALTA TIPS is a longitudinal observational study of patients who are undergoing transjugular intrahepatic portosystemic shunt (TIPS) placement. ALTA will create ...

9. A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional Therapies But Have Not Failed Biologic Therapy - Mayo Clinic

   The objective of this study is to evaluate the efficacy and safety of upadacitinib compared to placebo as induction therapy in participants with moderately and ...

10. A Study to Evaluate Effectiveness and Safety of Ustekinumab Re-induction Therapy in Participants With Moderate to Severely Active Crohn's Disease (POWER) - Mayo Clinic

    The primary purpose of this study is to evaluate the effectiveness and safety of a single intravenous (IV) re-induction dose of approximately 6 milligram per ...